The leukemogenic transcription factor E2a-Pbx1 induces expression of the putative N-myc and p53 target gene NDRG1 in Ba/F3 cells

被引:22
作者
Rutherford, MN
Bayly, GRL
Matthews, BP
Okuda, T
Dinjens, WMN
Kondoh, H
LeBrun, DP [1 ]
机构
[1] Queens Univ, Dept Pathol, Richardson Lab, Kingston, ON K7L 3N6, Canada
[2] Osaka Univ, Inst Mol & Cellular Biol, Osaka, Japan
[3] Erasmus Univ, Dept Pathol, NL-3000 DR Rotterdam, Netherlands
关键词
leukemia; E2a-Pbx1; Ndr1; RTP; NDRG1; representational difference analysis;
D O I
10.1038/sj.leu.2402059
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The chimeric transcription factor E2a-Pbx1 is expressed as a result of the 1;19 chromosomal translocation in some 5% of cases of pediatric acute lymphoblastic leukemia. We investigated the biological and transcriptional consequences of forced expression of E2a-Pbx1 in the interleukin-3 (IL-3) dependent, bone marrow-derived cell line Ba/F3. We show that forced expression of E2a-Pbx1 induces apoptosis in Ba/F3 cells without apparent effects on cell cycle progression. This pro-apoptotic effect is enhanced on cytokine deprivation. Furthermore, using cDNA representational difference analysis (RDA), we show that these cellular effects are associated with marked induction of the gene NDRG1, which was previously identified as a target of transcriptional repression by N-myc and induction by the tumor suppressor protein p53, We identity a portion of the NDRG1 promoter capable of mediating transcriptional induction by E2a-Pbx1 and show that NDRG1 is also Induced on simple IL-3 deprivation of BaF3 cells. Although we show that E2a-Pbx1 induction of NDRG1 is not impaired as a result of targeting p53 using HPV E6, and therefore does not appear to be p53-dependent, our results overall are consistent with the notion that induction of NDRG1 by E2a-Pbx1 may represent part of an apoptotic or cytostatic cellular response to oncogene activation.
引用
收藏
页码:362 / 370
页数:9
相关论文
共 42 条
[1]   THE E2A GENE-PRODUCT CONTAINS 2 SEPARABLE AND FUNCTIONALLY DISTINCT TRANSCRIPTION ACTIVATION DOMAINS [J].
ARONHEIM, A ;
SHIRAN, R ;
ROSEN, A ;
WALKER, MD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (17) :8063-8067
[2]   E2A deficiency leads to abnormalities in alpha beta T-cell development and to rapid development of T-cell lymphomas [J].
Bain, G ;
Enel, I ;
Maandag, ECR ;
teRiele, HPJ ;
Voland, JR ;
Sharp, LL ;
Chun, J ;
Huey, B ;
Pinkel, D ;
Murre, C .
MOLECULAR AND CELLULAR BIOLOGY, 1997, 17 (08) :4782-4791
[3]   E2A PROTEINS ARE REQUIRED FOR PROPER B-CELL DEVELOPMENT AND INITIATION OF IMMUNOGLOBULIN GENE REARRANGEMENTS [J].
BAIN, G ;
MAANDAG, ECR ;
IZON, DJ ;
AMSEN, D ;
KRUISBEEK, AM ;
WEINTRAUB, BC ;
KROP, I ;
SCHLISSEL, MS ;
FEENEY, AJ ;
VANROON, M ;
VANDERVALK, M ;
TERIELE, HPJ ;
BERNS, A ;
MURRE, C .
CELL, 1994, 79 (05) :885-892
[4]   GROWTH-FACTOR MODULATION OF P53-MEDIATED GROWTH ARREST VERSUS APOPTOSIS [J].
CANMAN, CE ;
GILMER, TM ;
COUTTS, SB ;
KASTAN, MB .
GENES & DEVELOPMENT, 1995, 9 (05) :600-611
[5]   PBX PROTEINS DISPLAY HEXAPEPTIDE-DEPENDENT COOPERATIVE DNA-BINDING WITH A SUBSET OF HOX PROTEINS [J].
CHANG, CP ;
SHEN, WF ;
ROZENFELD, S ;
LAWRENCE, HJ ;
LARGMAN, C ;
CLEARY, ML .
GENES & DEVELOPMENT, 1995, 9 (06) :663-674
[6]  
Cook DM, 1996, ONCOGENE, V13, P1789
[7]   The gene encoding the granulocyte colony-stimulating factor receptor is a target for deregulation in pre-B ALL by the t(1;19)-specific oncoprotein E2A-Pbx1 [J].
de Lau, WBM ;
Hurenkamp, J ;
Berendes, P ;
Touw, IP ;
Clevers, HC ;
van Dijk, MA .
ONCOGENE, 1998, 17 (04) :503-510
[8]   CHIMERIC HOMEOBOX GENE E2A-PBX1 INDUCES PROLIFERATION, APOPTOSIS, AND MALIGNANT-LYMPHOMAS IN TRANSGENIC MICE [J].
DEDERA, DA ;
WALLER, EK ;
LEBRUN, DP ;
SENMAJUMDAR, A ;
STEVENS, ME ;
BARSH, GS ;
CLEARY, ML .
CELL, 1993, 74 (05) :833-843
[9]  
DiMartino JF, 1999, BLOOD, V94, p652A
[10]   EB-1, a tyrosine kinase signal transduction gene, is transcriptionally activated in the t(1;19) subset of pre-B ALL, which express oncoprotein E2a-Pbx1 [J].
Fu, XY ;
McGrath, S ;
Pasillas, M ;
Nakazawa, S ;
Kamps, MP .
ONCOGENE, 1999, 18 (35) :4920-4929